MHB-018A Market Summary

Key Factors Driving MHB-018A Growth

1. Strong Phase I/II Clinical Efficacy Demonstrating Best-in-Class Potential

MHB-018A has shown highly encouraging efficacy in early clinical studies. According to data presented at ENDO 2026, the recommended 450 mg every-4-week (Q4W) regimen achieved:

• 81% proptosis response at Week 12 in patients with active TED.
• 76% proptosis response at Week 24 in patients with chronic TED.

These results compare favorably with historical outcomes reported for currently available IGF-1R-targeted therapies and support the drug's potential to become a differentiated or best-in-class treatment if confirmed in Phase III trials.

2. Convenient Subcutaneous Administration Improves Patient Access

Unlike currently marketed IGF-1R therapy, which requires multiple intravenous infusions, MHB-018A is formulated as a once-monthly subcutaneous injection. The molecule is based on a VHH-Fc (single-domain antibody) platform with high solubility (approximately 150 mg/mL), enabling convenient subcutaneous delivery. This has the potential to reduce infusion-center visits, lower healthcare resource utilization, improve patient adherence, and expand treatment accessibility if approved.

3. Differentiated Molecular Design with Enhanced Biological Activity

MHB-018A has been engineered to provide dual blockade of IGF-1 and IGF-2 signaling, addressing both ligands involved in IGF-1R pathway activation. According to Minghui Pharmaceutical, the molecule demonstrates 2- to 3-fold greater ligand-blocking potency than existing IGF-1R antibodies, while preclinical studies showed 3- to 5-fold stronger inhibition of IGF-mediated signaling. Enhanced receptor inhibition could translate into improved clinical efficacy and durability of response, strengthening its competitive positioning in the TED market.

4. Favorable Safety Profile Could Differentiate the Product

Safety remains an important competitive consideration for IGF-1R inhibitors. Across 98 treated patients in the Phase I/II program, MHB-018A was generally well tolerated. Importantly, all reported hearing-related adverse events were Grade 1, with no severe or permanent hearing damage observed. Given that hearing impairment has been a recognized concern with currently approved IGF-1R therapy, a favorable safety profile could become a significant adoption driver if maintained in pivotal studies.

5. Rapid Advancement into Global Phase III Development

MHB-018A has progressed rapidly through clinical development. Following positive Phase I/II results, the US FDA cleared the Investigational New Drug (IND) application to initiate global Phase III trials. The company reported:

• Ongoing Phase III trials in China, with top-line results expected in Q3 2026.
• Global Phase III enrollment scheduled to begin in Q4 2026.

Successful completion of these pivotal studies represents the key catalyst for regulatory approval and commercialization in major markets.

MHB-018A Recent Developments

In June 2026, Minghui Pharmaceutical presented complete Phase I/II clinical data of MHB018A, a novel subcutaneous anti-IGF-1R antibody, in patients with active and chronic thyroid eye disease ("TED"). The data were featured in an oral presentation at ENDO 2026, the Endocrine Society's Annual Meeting (Chicago, USA).

“MHB-018A Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of MHB-018A for potential indication like Graves ophthalmopathy in the 7MM. A detailed picture of MHB-018A’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the MHB-018A for potential indications. The MHB-018A market report provides insights about MHB-018A’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current MHB-018A performance, future market assessments inclusive of the MHB-018A market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of MHB-018A sales forecasts, along with factors driving its market.

MHB-018A Drug Summary

MHB-018A is an investigational humanized monoclonal antibody being developed by Minghui Pharmaceutical for the treatment of thyroid eye disease (TED). The antibody selectively targets the insulin-like growth factor-1 receptor (IGF-1R), a key mediator of the autoimmune signaling that drives orbital inflammation, fibroblast activation, adipogenesis, and tissue remodeling in TED. By inhibiting IGF-1R signaling, MHB-018A is intended to reduce proptosis, clinical disease activity, diplopia, and other ophthalmic manifestations while preserving normal immune function. Administered by intravenous infusion, MHB-018A is being evaluated in clinical studies for its safety, pharmacokinetics, immunogenicity, and efficacy in patients with active TED. As of 2026, the therapy is in Phase III clinical development in China following encouraging early-stage clinical results demonstrating meaningful reductions in proptosis and Clinical Activity Score (CAS), and it remains investigational without regulatory approval. The report provides MHB-018A’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the MHB-018A Market Report

The report provides insights into:

• A comprehensive product overview including the MHB-018A MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy.
• Elaborated details on MHB-018A regulatory milestones and other development activities have been provided in MHB-018A market report.
• The report also highlights MHB-018A‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The MHB-018A market report also covers the patents information, generic entry and impact on cost cut.
• The MHB-018A market report contains current and forecasted MHB-018A sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The MHB-018A market report also features the SWOT analysis with analyst views for MHB-018A in potential indications.

Methodology

The MHB-018A market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MHB-018A Analytical Perspective by DelveInsight

• In-depth MHB-018A Market Assessment

This MHB-018A sales market forecast report provides a detailed market assessment of MHB-018A for potential indication like Graves ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted MHB-018A sales data uptil 2034.

• MHB-018A Clinical Assessment

The MHB-018A market report provides the clinical trials information of MHB-018A for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

MHB-018A Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

MHB-018A Market Potential & Revenue Forecast

• Projected market size for the MHB-018A and its key indications
• Estimated MHB-018A sales potential (MHB-018A peak sales forecasts)
• MHB-018A Pricing strategies and reimbursement landscape

MHB-018A Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• MHB-018A Market positioning compared to existing treatments
• MHB-018A Strengths & weaknesses relative to competitors

MHB-018A Regulatory & Commercial Milestones

• MHB-018A Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

MHB-018A Clinical Differentiation

• MHB-018A Efficacy & safety advantages over existing drugs
• MHB-018A Unique selling points

MHB-018A Market Report Highlights

• In the coming years, the MHB-018A market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The MHB-018A companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MHB-018A’s dominance.
• Other emerging products for Graves ophthalmopathy are expected to give tough market competition to MHB-018A and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MHB-018A in potential indications.
• Analyse MHB-018A cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted MHB-018A sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of MHB-018A in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of MHB-018A? How strong is MHB-018A’s clinical and commercial performance?
• What is MHB-018A’s clinical trial status in each individual indications such as Graves ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MHB-018A Manufacturers?
• What are the key designations that have been granted to MHB-018A for potential indications? How are they going to impact MHB-018A’s penetration in various geographies?
• What is the current and forecasted MHB-018A market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of MHB-018A in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to MHB-018A for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is MHB-018A? What is the duration of therapy and what are the geographical variations in cost per patient?